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Supplementary Table 1. NE-FFN Candidates and pKa’s.
List of FFN candidates tested for NET substrate activity.
pKa was determined by measuring the change in











Supplementary Table 2. Primary Screen of
FFN270 binding at 54 CNS Receptors. FFN270 (10
µM) was tested at 54 CNS receptors in
collaboration with the Psychoactive Drug
Screening Program (PDSP). Data represent mean
% inhibition (N = 4 determinations) for FFN270
tested at receptor subtypes. Values greater than
50% are considered significant.1
5-HT1A 5.7 Beta1 -17.3
5-HT1B 37.3 Beta2 -7.9
5-HT1D -4 Beta3 -2.7
5-ht1e 11.5 D1 -2.5
5-HT2A 6.3 D2 -3.5
5-HT2B 3.5 D3 3.7
5-HT2C 2.5 D4 20.7
5-HT3 -8.5 D5 10.7
5-HT4 -2.8 DAT 34.2
5-ht5a 2.6 DOR 6.7
5-HT6 -4.4 GABAA 10.5
5-HT7 2.5 H1 5.6
A2B2 -3.4 H2 14.6
A2B4 5.5 H3 13.6
A3B2 -8.6 H4 2.8
A3B4 5.1 HERG binding -4
A4B2 -3.6 KOR 7.3
A4B2 3.8 M1 5.6
A4B4 4.6 M2 -0.6
A7 -28.4 M3 -12.2
A7 6 M4 10.1
Alpha1A -4.2 M5 1.5
Alpha1B 2.3 MOR 15.7
Alpha1D -6.2 NET 14.3
Alpha2A -2 SERT -9
Alpha2B -13.7 Sigma 1 -4.9
Alpha2C -8.5 Sigma 2 2.2
Supplementary Figure 1. FFN270 absorbance and emission spectra.
A) Absorbance spectrum was obtained using 40 µM solutions of
FFN270 in PBS buffer with pH values ranging from 3 to 10. B)
Emission spectrum was obtained using 0.2 µM FFN270 solutions in





































































































































































































Supplementary Figure 2. FFN202 and FFN102 in vivo. Structures of
FFN202 (A) and FFN102 (E), the first FFNs to be tested in vivo (Wenbio
Gan, NYU). Two-photon fluorescence images of FFN202 (B) and FFN102
(D) taken in Layer 1 of the somatosensory cortex. Red arrow: cell body,
Blue arrow: axonal structure. C) 3-D reconstruction of FFN202 labeling in
the outermost 100 µm of somatosensory cortex. More axonal structures




Supplementary Figure 3. FFN270 staining in hNET-HEK cells.
Fluorescence (left) and corresponding bright-field images (right) of
hNET-transfected HEK cells treated with 20 μM FFN270 in the
absence (A) or presence of nomifensine (2 μM, B) or cocaine (1 μM,










Supplementary Figure 4. FFN270 uptake through hNET, hDAT, and
hSERT. Fluorescence and bright-field images of HEK cells
transfected with hNET, hDAT, or hSERT. A-C) Cells are treated with
20 μM FFN270. D-F) As a positive control, the same cell lines are
treated with 1 μM APP+, a known fluorescent substrate of all three














Supplementary Figure 5. FFN202 and 093 staining Layer
1 of the barrel cortex in acute murine brain slice.
Representative images of FFN202 (A) and 093 (B) in
Layer 1 of the barrel cortex following a 30 min
incubation (10 µM). Highlighted with red arrows are
labeled axon structures. Scale Bar: 10 µm.
A.
B.
Supplementary Figure 6. ChR2-YFP expression in NE-
neurons and colocalization with FFN270. ChR2-YFP was
expressed in noradrenergic neurons as described in the
Methods, and then the YFP was imaged in the barrel
cortex as a positive marker for noradrenergic
projections (B). A) FFN270 staining in the same area. C)
colocalization between the two channels can be
observed in some axons (highlighted with blue arrow)





FFN270 release in acute
brain slice. A) Acute slices
were loaded with FFN270
and then imaged every 1
min. The average change in
fluorescence of FFN270
puncta was measured
during the course of an
amphetamine (AMPH, 10
µM), nomifensine (Nom., 2
µM), or ACSF perfusion
(starting at t = 0). B) The
number of selected FFN270
puncta before and 5 min
after AMPH was significantly
different compared to
controls (P < 0.0001, one-
way ANOVA Dunnett post-
hoc) while Nom. perfusion
showed no difference (P =
0.95). Data from each
condition is collected from
2-3 slices per animal from 3
animals, and presented with
min to max whiskers.
Representative FFN270
images before and 5 min
after ACSF (C-D), Nom. (E-F),
or AMPH (G-H) perfusion.
Scale bar: 10 µm.






























































Supplementary Figure 8. Colocalization of FFN270 with
blood vessels. A-B) Two representative pairs of low zoom
images highlighting colocalization between FFN270
(magenta) and lectin stained vasculature (green) across
Layers 2-6 of the barrel cortex. Note that there is not
perfect overlap between channels as the FFN270 images
were collected in healthy acute brain slices, and the lectin
stain was performed on those same slices post-fixation.
Some clearer examples have been highlighted by red






Comparison of FFN102 and
FFN270 loading in dorsal
striatum and barrel cortex.
A-B) Acute slices containing
the dorsal striatum (DS) were
loaded with a high incubation
dose (50 µM) of either
FFN102 (green) or FFN270
(magenta), and colocalization
with the tdTomato reporter
(red) in DAT-positive neurons
was determined (see
Methods for details). We
observed much stronger
FFN102 signal in the DS
compared to FFN270, even at
this elevated dose. C-D) This
comparison was repeated in
the barrel cortex, where we
observed almost no
dopamine axons (small
scattered spots are likely
autofluorescence). In this
brain region, we observed
insignificant FFN102 uptake
compared to FFN270, even










Supplementary Figure 10. Effect of optogenetic stimulation frequency
on FFN270 release. Acute murine brain slices containing Layer 1-3 of
the barrel cortex were collected from TH-Cre/Ai32 animals expressing
ChR2-EYFP in monoaminergic neurons. A-B) Representative images of
FFN270 before (A) and after (B) 4 min of 1 Hz 470 nm light stimulation
(5 ms duration, 240 pulses). C-D) Representative images of FFN270
before (A) and after (B) 4 min of 10 Hz 470 nm light stimulation (5 ms
duration, 2,400 pulses). E) Change in fluorescence of individual axons
was quantified and then grouped depending on colocalization with the
EYFP reporter. Average release ± SEM following 10 Hz (65.4 ± 3.0%) and
1 Hz (55.5 ± 3.0%) were not significantly different each other (Mann-
Whitney, P = 0.07, n = 2 slices per condition per animal, 4 animals) and






























































Supplementary Figure 11. FFN270 Loading in Bed Nuclei of the Stria
Terminalis. A) Atlas image highlighting in red the location of the bed
nuclei of the stria terminalis (BST) in the mouse brain (Bregma: -0.5
mm, Allen Institute).2 B) FFN270 (10 µM) labeling pattern in the BST
following 30 min incubation. Scale Bar: 10 µm.
B.A.
Bregma: -0.5 mm
Supplementary Figure 12. FFN270 Electrical Stimulation with Cadmium
ions. A representative set of images highlighting the change in FFN270
fluorescence signal over the course of a 10 Hz electrical stimulus while
blocking calcium channels with cadmium chloride (200 µM). See Figure 5
as a comparison with control FFN270 fluorescent changes. Scale Bar: 5
µm.
-60 s -30 s 0 s
30 s 60 s 90 s
  
Supplementary Figure 13. Synthesis of 093. Formylation of flourodimethoxybenzene 1 
was carried out using a modified Vilsmeier-Haack reagent. After a selective deprotection 
of methoxy group in position 2 using boron tribromide, the free hydroxyl group of 3 was 
acylated with Boc-protected GABA in DIC mediated/DMAP catalyzed process. 
Cyclization of ester-aldehyde 4 in the presence of a catalytic amount of phosphaza-
superbase and molecular sieves as a water scavenger yielded the coumarin 5. Final 
deprotection of both Boc and methoxy group was achieved by heating the protected 
coumarin 5 with mixture of hydrobromic and acetic acid. HPLC purification and anion 
exchange yielded the final probe 093 as an HCl salt. 
 
Supplementary Figure 14. Synthesis of 269 and FFN270. Commercially available 2-
haloresorcinols 6 were protected by methylation. 2-Halodimethoxybenzenes 7 were 





























2. HCl (0.1 M)
X = Cl - AGH269















10a  - Cl
10b  - F
11a - Cl







































2. HCl (0.1 M)
AGH093
Cl
551 % 75 %   093 
  
Supplementary Methods. Synthesis and Characterization of the Probes. Unless 
otherwise noted, all chemicals were purchased from commercial companies and used 
without further purification. Nuclear Magnetic Resonance spectra were recorded on 
Bruker 400 and 500 MHz Fourier transform NMR spectrometers. Proton chemical shifts 
δ are expressed in parts per million (ppm) and are referenced to residual proton in the 
NMR solvent (CDCl3, δ = 7.26 ppm; CD3OD, δ = 3.31 ppm; (CD3)2SO, δ = 2.50 ppm; 
(CD3)2CO, δ = 2.05 ppm; D2O, δ = 4.79 ppm). Data for 1H NMR and 19F NMR are 
reported as follows: chemical shift, integration, multiplicity (s = singlet, d = doublet, t = 
triplet, m = multiplet, br = broad peak, app = apparent), and coupling constant in Hz. 
Carbon chemical shifts are referenced to the carbon resonance of the NMR solvent 
(CDCl3, δ = 77.2 ppm; CD3OD, δ = 49.0 ppm; (CD3)2SO, δ = 39.5 ppm; (CD3)2CO, δ = 
29.8 ppm). 13C NMR spectra were recorded without 19F decoupling and therefore JCF 
splitting of 13C signals was observed for fluorinated compounds. Low-resolution mass 
spectra were recorded on a JEOL LCmate instrument in APCI+ ionization mode (Note: 
Mass spectra of Boc-protected compounds are reported for carbocations corresponding to 
loss of Boc fragment). High-resolution mass spectra (HR-MS) were recorded on a JOEL 
HX110 mass spectrometer in FAB ionization mode. 
Preparative HPLC was performed on Waters 600 Controller equipped with a 
Vydac C18 Protein & Peptide column (mobile phase – gradient of solvents A and B, 
where A = deionized water containing 0.1% (v/v) formic acid (FA); B = HPLC grade 
methanol containing 0.1% (v/v) formic acid (FA)), Waters 2487 Dual Wavelength 
Absorbance Detector (λ = 254 nm) and Waters 2767 Sample Manager. Analytical HPLC 
was performed on the same instrument equipped with a Phenomenex reverse phase 
column (Prodigy 5 micron ODS3 100A 250 x 4.6 mm) using isocratic methanol:water 
(30:70) mobile phase. All probes were purified by preparative HPLC in the final stage 
and converted to a hydrochloride salt. The hydrochloride salts of final fluorophores were 
prepared by treating the formate salts with 4-6 molar excess of HCl (0.1 M) followed by 
concentration and lyophilization. The HCl salts were obtained as white powder.1,2  





POCl3 (0.60 mL, 6.40 mmol) was dropwise added to N-methylformanilide 
(0.79 mL, 6.40 mmol) and the resulting mixture was stirred at room 
temperature for 30 min.  2,4-Dimethoxyflurobenzene 1 (0.84 mL, 6.40 mmol) was then 
added and the mixture was heated to 35 °C for 3 h. After an overnight stirring at room 
temperature the reaction mixture was poured into ice-water. The white precipitate was 
collected by filtration and crystallized from cyclohexane affording the product as a white 
crystals (1.05 g, 89%). 1H NMR (400 MHz, Acetone-d6) δ 10.25 (d, J = 3.3 Hz, 1H), 
7.41 (d, J = 11.3 Hz, 1H), 6.95 (d, J = 6.7 Hz, 1H), 4.03 (s, 3H), 4.01 (s, 3H). 
 
5-Fluoro-2-hydroxy-4-methoxybenzaldehyde (3) 
BBr3 (1.0 M solution in CH2Cl2, 0.9 mL, 0.9 mmol) was slowly added to an 
ice-cold solution of 2 (125 mg, 0.68 mmol) in dry CH2Cl2 (8 mL) under 
argon protection. The reaction mixture was then stirred at room temperature for 15 h, 
diluted with water and extracted with EtOAc (3x15 ml). The combined organic layers 
were dried over MgSO4 and concentrated. The crude product was purified by column 
chromatography (hexane:CH2Cl2 – 1:2). The product 3 was obtained as a white solid (105 
mg, 87%). 1H NMR (400 MHz, Acetone-d6) δ 9.81 (d, J = 0.3 Hz, 1H), 7.52 (d, J = 10.9 
Hz, 1H), 6.68 (d, J = 7.0 Hz, 1H), 4.00 (s, 3H).5 
 
 4-Fluoro-2-formyl-5-methoxyphenyl 4-((tert-butoxycarbonyl) 
amino)butanoate (4) 
To a solution of compound 3 (130 mg, 0.76 mmol), Boc-GABA-
OH (185 mg g, 0.92 mmol) and 4-(dimethylamino)pyridine (10 mg) in CH2Cl2 (12 mL) 
was added N,N′-diisopropylcarbodiimide (0.16 mL, 1.0 mmol). The reaction mixture was 
stirred at room temparature for 1.5 h, washed with H2O, brine and dried over MgSO4. 
The crude product was purified by column chromatography (CH2Cl2 + 3% acetone) 
affording the compound 4 as a white solid (265 mg, 98%). 1H NMR (400 MHz, 
Acetone-d6) δ 10.00 (d, J = 1.6 Hz, 1H), 7.59 (d, J = 11.1 Hz, 1H), 7.17 (d, J = 7.1 Hz, 
1H), 6.09 (br s, 1H), 4.00 (s, 3H), 3.22 (q, J = 6.5 Hz, 2H), 2.76 (t, J = 7.3 Hz, 2H), 1.91 
















10.4, 7.1, 2.2 Hz); 13C NMR (101 MHz, Acetone-d6) δ 187.5, 172.3, 157.0, 154.3, 154.2, 
152.0, 150.8, 149.6, 122.3, 115.9, 115.7, 109.9, 78.6, 57.3, 40.0, 31.5, 28.7, 26.0. HR-
MS calcd. for C17H22FNNaO6 [M+Na]




To a suspension of compound 4 (390 mg, 1.1 mmol) and activated 
3Å molecular sieves (powder, 1.5 g) in dry benzene (10.0 mL) was added 2,8,9-
triisopropyl-2,5,8,9-tetraaza-1-phospha- bicyclo[3.3.3]undecane (170 mg, 0.51 mmol) in 
dry benzene (5.0 mL) via syringe at 50 °C. After being stirred at 50 °C under argon for 
16 h, the reaction mixture was cooled to RT, diluted with CH2Cl2 (20 mL), filtered 
through celite and concentrated. Purification by column chromatography (hexane:ethyl 
acetate – 5:2) yielded compound 5 as a white solid (205 mg; 55%). 1H NMR (400 MHz, 
Acetone-d6) δ 7.63 (s, 1H), 7.39 (d, J = 11.0 Hz, 1H), 7.09 (d, J = 7.2 Hz, 1H), 6.07 (br s, 
1H), 4.00 (s, 3H), 3.36 (q, J = 6.3 Hz, 2H), 2.66 (t, J = 6.4 Hz, 2H), 1.31 (s, 9H); 19F 
NMR (376 MHz, Acetone-d6) δ -140.10 (dd, J = 10.9, 7.3 Hz); 13C NMR (101 MHz, 
Acetone-d6) δ 161.7, 156.7, 151.7, 150.9, 148.5, 140.0, 125.6, 113.8, 113.6, 113.1, 113.0, 




hydrochloride salt (093) 
A solution of compound 5 (65 mg, 0.185 mmol) in AcOH (1.5 mL) 
and HBr (1.5 mL) was heated in closed vial to 110 °C for 38 h. The 
reaction mixture was then concentrated and the crude product was purified by reverse 
phase HPLC using a linear gradient - water (A), MeOH (B) (25% B → 95% over 20 min). 
The fractions containing the product (retention time ~ 8.7 min) were collected, 
concentrated, and converted to an HCl salt according to general procedure (General 
remarks). Final compound 093 was obtained as a white solid (37 mg, 75%). 1H NMR 
(400 MHz, D2O) δ 7.85 (s, 1H), 7.41 (d, J = 10.7 Hz, 1H), 7.01 (d, J = 7.2 Hz, 1H), 3.32 
(t, J = 7.2 Hz, 2H), 2.93 (t, J = 7.2 Hz, 2H); 19F NMR (376 MHz, D2O) δ -138.95 (dd, J 










    093 
  
148.6, 144.2, 144.1, 121.4, 114.8, 114.6, 113.0, 112.9, 105.7, 105.7, 39.0, 29.3; HR-MS 
calcd. for C11H11FNO3 [M+H]
+ 224.0717, found 224.0722. 
 
 
 2-Chloro-1,3-dimethoxybenzene (7a) 
To a suspension of 6a (0.85 g, 5.9 mmol) and freshly dry K2CO3 (1.8 g, 13 
mmol) in dry acetone (35 ml) was added MeI (1.5 mL, 23.6 mmol) and the 
reaction flask was sealed with a teflon cap. The resulting mixture was heated to 50 °C for 
20 h. Inorganic salts were removed by filtration, washed with acetone and the solution 
was concentrated. The crude product was dissolved in boiling hexane (~20 mL) and 
insoluble solid was filtered and washed with hot hexane (~2 x 5 mL). After cooling to 
0 °C the compound 7a crystalized as a white prism (0.92 g, 91%). 1H NMR (400 MHz, 
Acetone-d6) δ 7.23 (t, J = 8.4 Hz, 1H), 6.74 (d, J = 8.4 Hz, 2H), 3.87 (s, 6H).6 
 
2-Fluoro-1,3-dimethoxybenzene (7b) 
To a suspension of 6b (1.0 g, 7.80 mmol) and freshly dry K2CO3 (1.97 g, 
14.1 mmol) in dry acetone (35 ml) was added MeI (1.6 mL, 25.6 mmol) 
and the reaction flask was sealed with a teflon cap. The resulting mixture was heated to 
50 °C for 20 h. Inorganic salts were removed by filtration, washed with acetone and the 
solution was concentrated. The crude product was dissolved in boiling hexane (~20 mL) 
and insoluble solid was filtered, washed with hot hexane (~2 x 5 mL) and the solution 
was again concentrated. The crude product was purified by column chromatography 
(hexane:ethyl acetate – 7:1). The product 7b was obtained as a colorless oil (1.1 g, 90%). 
1H NMR (500 MHz, Acetone-d6) δ 7.02 (td, J = 8.5, 2.3 Hz, 1H), 6.73 (dd, J = 8.4, 7.4 
Hz, 2H), 3.85 (s, 6H).7 
 
 3-Chloro-2,4-dimethoxybenzaldehyde (8a) 
The compound 8a was prepared from 7a (750 mg, 4.35 mmol) in the same 
way as compound 2. The crude product was purified by column 
chromatography (hexane:ethyl acetate – 7:1). The product 8a was obtained as a white 












Acetone-d6) δ 10.20 (d, J = 0.6 Hz, 1H), 7.77 (d, J = 8.8 Hz, 1H), 7.11 (d, J = 8.8 Hz, 
1H), 4.03 (s, 3H), 4.01 (s, 3H).8 
 
 3-Fluoro-2,4-dimethoxybenzaldehyde (8b) 
The compound 8b was prepared from 7b (1.0 g, 6.4 mmol) in the same 
way as compound 2. The crude product was purified by column 
chromatography (hexane:ethyl acetate – 7:1). The product 8b was obtained as a white 
solid (570 mg, 48%; 105 mg of starting material was recovered). 1H NMR (400 MHz, 
Acetone-d6) δ 10.20 (s, 1H), 7.57 (dd, J = 8.9, 2.1 Hz, 1H), 7.03 (app t, J = 7.9 Hz, 1H), 
4.09 (d, J = 2.2 Hz, 3H), 4.00 (s, 3H).9 
  
3-Chloro-2-hydroxy-4-methoxybenzaldehyde (9a) 
The compound 9a was prepared from 8a (90 mg, 0.45 mmol) in the same 
way as compound 3 in 3 h. The crude product was purified by column 
chromatography (CH2Cl2:hexane – 1:1). The product 9a was obtained as a white solid (70 
mg, 84%).1H NMR (400 MHz, Acetone-d6) δ 11.67 (br s, 1H), 9.87 (s, 1H), 7.77 (d, J = 
8.8 Hz, 1H), 6.92 (d, J = 8.8 Hz, 1H), 4.04 (s, 3H).10 
 
3-Fluoro-2-hydroxy-4-methoxybenzaldehyde (9b) 
The compound 9b was prepared from 8b (520 mg, 2.82 mmol) in the same 
way as compound 3 in 2 h. The crude product was purified by column 
chromatography (CH2Cl2:hexane – 1:1). The product 9a was obtained as a white solid (70 
mg, 84%). 1H NMR (400 MHz, Acetone-d6) δ 11.10 (br s, 1H), 9.90 (d, J = 1.8 Hz, 1H), 
7.59 (dd, J = 8.8, 2.0 Hz, 1H), 6.90 (dd, J = 8.8, 7.0 Hz, 1H), 4.01 (s, 3H); 19F NMR (376 
MHz, Acetone-d6) δ -161.89 (dt, J = 7.0, 1.9 Hz); 13C NMR (101 MHz, Acetone-d6) δ 
196.6, 196.5, 155.4, 155.3, 151.0, 150.9, 141.9, 139.5, 130.9, 130.9, 117.6, 117.6, 105.6, 
57.1; HR-MS calcd. for C8H6FO3 [M-H]
























the same way as compound 4. The crude product was purified by column 
chromatography (CH2Cl2 + 3% acetone). The product 10a was obtained as a white solid 
(105 mg, 88%). 1H NMR (400 MHz, Acetone-d6) δ 9.99 (s, 1H), 7.89 (d, J = 8.8 Hz, 
1H), 7.27 (d, J = 8.8 Hz, 1H), 6.12 (br s, 1H), 4.07 (s, 3H), 3.23 (q, J = 6.6 Hz, 2H), 2.82 
(q, J = 6.1, 5.2 Hz, 2H, overlaps with acetone residual peak), 1.99 – 1.91 (m, 2H), 1.41 (s, 
9H); 13C NMR (101 MHz, Acetone) δ 188.2, 171.2, 161.5, 156.8, 131.5, 124.2, 110.6, 
78.6, 57.5, 40.2, 31.5, 30.1, 28.6, 26.0; HR-MS calcd. for C17H22ClNNaO6 [M+Na]
+ 




The compound 10b was prepared from 9b (230 mg, 1.35 mmol) 
in the same way as compound 4. The crude product was purified by column 
chromatography (CH2Cl2 + 3% acetone). The product 10b was obtained as a white solid 
(445 mg, 93%). 1H NMR (400 MHz, Acetone-d6) δ 10.01 (s, 1H), 7.73 (dd, J = 8.8, 2.0 
Hz, 1H), 7.27 (dd, J = 8.6, 7.6 Hz, 1H), 6.11 (br s, 1H), 4.04 (s, 3H), 3.22 (q, J = 6.6 Hz, 
2H), 2.81 (t, J = 7.4 Hz, 2H overlaps with acetone residual peak), 1.94 (p, J = 7.1 Hz, 
3H), 1.41 (s, 9H); 19F NMR (376 MHz, Acetone-d6) δ -151.00 (d, J = 7.1 Hz); 13C NMR 
(101 MHz, Acetone-d6) δ 188.3, 188.3, 171.2, 156.8, 154.5, 154.4, 146.4, 144.0, 127.8, 
123.7, 111.4, 100.9, 78.6, 57.3, 40.2, 31.4, 28.6, 26.0; HR-MS calcd. for C17H22FNNaO6 




The compound 11a was prepared from 10a (100 mg, 0.27 mmol) in 
the same way as compound 5. The crude product was purified by column 
chromatography (CH2Cl2 + 2% acetone). The product 11a was obtained in mixture with 
Boc-GABA-OH (~1:3) as a colorless viscous oil and was used in the final step without 
further purification (25 mg, 26%, of 11a based on an 1H NMR ratio). 1H NMR (400 
MHz, Acetone-d6) δ 7.69 (s, 1H), 7.57 (d, J = 8.7 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.12 












J = 6.3 Hz, 2H), 2.40 (t, J = 8.1 Hz, 6H)-GABA, 1.98 (p, J = 7.6 Hz, 6H)-GABA, 1.47 (s, 
27H)-GABA, 1.31 (s, 9H); LR-MS calcd. for C12H13ClNO3 [M+H-Boc]






The compound 11b was prepared from 10b (430 mg, 1.21 mmol) in 
the same way as compound 5. The crude product was purified by column 
chromatography (hexane:ethyl acetate – 5:2). The product 11b was obtained as a white 
solid (165 mg, 40%). 1H NMR (400 MHz, Acetone-d6) δ 7.69 (d, J = 0.9 Hz, 1H), 7.39 
(dd, J = 8.8, 2.1 Hz, 1H), 7.14 (dd, J = 8.7, 7.5 Hz, 1H), 6.11 (br s, 1H), 3.99 (s, 3H), 
3.37 (q, J = 6.3 Hz, 2H), 2.67 (td, J = 6.4, 0.8 Hz, 2H), 1.31 (s, 9H); 19F NMR (376 
MHz, Acetone-d6) δ -158.63 – -158.69 (m); 13C NMR (101 MHz, Acetone-d6) δ 160.8, 
156.7, 150.6, 150.5, 143.3, 143.2, 141.0, 140.5, 138.6, 125.2, 123.4, 123.3, 115.4, 110.0, 
78.6, 57.2, 39.2, 32.8, 28.6; HR-MS calcd. for C17H20FNNaO5 [M+Na]
+ 360.1223, found 
360.1227. 
3-(2-Aminoethyl)-8-chloro-7-hydroxy-2H-chromen-2-one 
hydrochloride salt (269) 
A solution of compound 11a (15 mg, 0.042 mmol) in AcOH (0.5 mL) 
and HBr (0.5 mL) was heated in closed vial to 110 °C for 48 h. The 
reaction mixture was then concentrated and the crude product was purified by reverse 
phase HPLC using a linear gradient - water (A), MeOH (B) (25% B → 95% over 20 min). 
The fractions containing the product (retention time ~ 9.7 min) were collected, 
concentrated, and converted to an HCl salt according to general procedure (General 
remarks). Final compound 269 was obtained as a white solid (7 mg, 61%). 1H NMR (400 
MHz, D2O) δ 7.88 (s, 1H), 7.44 (d, J = 8.7 Hz, 1H), 7.01 (d, J = 8.6 Hz, 1H), 3.34 (t, J = 
7.2 Hz, 2H), 2.94 (t, J = 7.1 Hz, 2H); 13C NMR (101 MHz, D2O/CD3OD) δ 164.2, 
156.6, 150.9, 144.5, 128.1, 120.5, 114.4, 114.1, 107.8, 38.9, 29.2; HR-MS calcd. for 
C11H11ClNO3 [M+H]














hydrochloride salt (FFN270) 
A solution of compound 11b (20 mg, 0.059 mmol) in AcOH (0.5 mL) 
and HBr (0.5 mL) was heated in closed vial to 110 °C for 48 h. The 
reaction mixture was then concentrated and the crude product was purified by reverse 
phase HPLC using a linear gradient - water (A), MeOH (B) (25% B → 95% over 20 min). 
The fractions containing the product (retention time ~ 8.4 min) were collected, 
concentrated, and converted to an HCl salt according to general procedure (General 
remarks). Final compound FFN270 was obtained as a white solid (12 mg, 78%). 1H 
NMR (400 MHz, D2O) δ 7.90 (s, 1H), 7.31 (dd, J = 8.7, 1.8 Hz, 1H), 7.01 (dd, J = 8.2, 
0.5 Hz, 1H), 3.33 (t, J = 7.2 Hz, 2H), 2.94 (t, J = 7.2 Hz, 2H); 19F NMR (376 MHz, 
D2O) δ -159.24 (dt, J = 7.7, 1.5 Hz); 13C NMR (101 MHz, D2O/CD3OD) δ 164.0, 148.1, 
148.0, 144.5, 144.5, 143.2, 143.2, 140.3, 137.9, 124.3, 124.3, 120.9, 115.4, 114.3, 39.0, 
29.4; HR-MS calcd. for C11H11FNO3 [M+H]
+ 224.0717, found 224.0732. 
 
Supplementary Figures 15-40. NMR Spectra. 










Supplementary Figure 16. 13C-NMR of compound 4 
 




Supplementary Figure 18. 1H-NMR of compound 5 
 




Supplementary Figure 20. 19F-NMR of compound 5 
 




Supplementary Figure 22. 13C-NMR of compound 093 
 




Supplementary Figure 24. 1H-NMR of compound 9b 
 




Supplementary Figure 26. 19F-NMR of compound 9b 
 




Supplementary Figure 28. 13C-NMR of compound 10a 
 




Supplementary Figure 30. 13C-NMR of compound 10b 
 




Supplementary Figure 32. 1H-NMR of compound 11a 
 




Supplementary Figure 34. 13C-NMR of compound 11b 
 




Supplementary Figure 36. 1H-NMR of compound 269 
 




Supplementary Figure 38. 1H-NMR of compound FFN270 
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